logo
FDA shares reminder of recalled Gerber teething sticks after product still seen on shelves

FDA shares reminder of recalled Gerber teething sticks after product still seen on shelves

USA Today19-04-2025

FDA shares reminder of recalled Gerber teething sticks after product still seen on shelves 'We sincerely apologize for any concern or inconvenience this action represents to parents, caregivers and retail customers,' Gerber said.
Show Caption
Hide Caption
Tips to help manage food recalls and prevent foodborne illnesses
About 128,000 are hospitalized and 3,000 people die each year from preventable foodborne illnesses.
Payton, USA TODAY
Well-known baby product maker Gerber Products Company issued a recall reminder in tandem with the Food and Drug Administration (FDA) on April 18 after affected products were still seen on store shelves.
The original voluntary recall was initiated on Jan. 31 after the company received complaints of choking incidents resulting in at least one known emergency room visit. Gerber discontinued the production of the impacted items.
The company chose to issue a second press release concerning the recall because it recently received reports that the recalled products were still available for sale on some retailers' shelves and online.
"We have been working with the U.S. Food & Drug Administration (FDA) on this recall and will cooperate with them fully," Gerber said in the second press release. "Again, we sincerely apologize for any concern or inconvenience this action represents to parents, caregivers and retail customers."
Here's what to know about the recall.
Which Geber products were recalled?
Gerber Snacks for Baby soothe 'n' chew Teething Sticks, Strawberry Apple, Net Wt 3.2 Oz (90g), with UPC 0 15000 04618 7, all lot codes
Gerber Snacks for Baby soothe 'n' chew Teething Sticks, Banana, Net Wt 3.2 Oz (90g), with UPC 0 15000 04608 8, all lot codes
Gerber Snacks for Baby soothe 'n' chew Teething Sticks, Banana, Net Wt 1.58 Oz (45g), with UPC 0 15000 01015 7, all lot codes
What to do if you have recalled products or see them on shelves
Consumers who previously purchased Geber Soothe N Chew Teething Stick should not give it to their children. Instead, they can return the product to the store from which they purchased it for a full refund, the company said. If you spot the recalled products still for sale, do not buy them, the company added.
For questions or support, Gerber can be contacted at 1-800-4-GERBER (1-800-443-7237).
Where were the recalled Gerber products distributed?
The teething sticks were distributed nationwide via online shops, Gerber said. They were also sent to physical retailers in Puerto Rico and the following states:

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA looks to AI to enhance efficiency
FDA looks to AI to enhance efficiency

Boston Globe

time32 minutes ago

  • Boston Globe

FDA looks to AI to enhance efficiency

Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The agency plays a central role in pursuing the agenda of the US health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Advertisement Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that AI is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. Advertisement 'I don't want to be dismissive of speeding reviews at the FDA,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' A major AI rollout closely follows the release of a report by Kennedy's MAHA Commission, which uses an acronym for Make America Healthy Again, that was found to be rife with references to scientific research apparently fabricated by an AI program. For some cases, the FDA officials proposed speeding major drug approvals by requiring only one major study in patients rather than two, a practice the agency has used in recent years. The pandemic provided a precedent, they said, for accelerating the process. 'We believe this is clear demonstration that rapid or instant reviews are possible,' Makary and Prasad wrote. But Holland pointed out that during the pandemic, many staff members were transferred from routine duties, including overseas inspections of food or drug facilities, and reassigned to hasten critical COVID product reviews. The agency was also better staffed. In recent months, the FDA shed about 1,940 employees, reducing the workforce to 8,000 from roughly 10,000. Last week, the agency introduced Elsa, an AI large-language model similar to ChatGPT. The FDA said it could be used to prioritize which food or drug facilities to inspect, to describe side effects in drug safety summaries and to perform other basic product-review tasks. The FDA officials wrote that AI held the promise to 'radically increase efficiency' in examining as many as 500,000 pages submitted for approval decisions. Advertisement Current and former health officials said the AI tool was helpful but far from transformative. For one, the model limits the number of characters that can be reviewed, meaning it is unable to do some rote data analysis tasks. Its results must be checked carefully, so far saving little time. Staff members said the model was hallucinating, or producing false information. Employees can ask the Elsa model to summarize text or act as an expert in a particular field of medicine. Makary said the AI models were not being trained by data submitted by the drug or medical device industry. When it comes to food oversight, Makary and Prasad said there would be a renewed focus on 'our increasingly chemically manipulated diet,' a goal embraced by Republicans and Democrats. 'For all additives,' the article said, 'the benefit-to-harm balance must be reevaluated.' Although the Trump administration is seeking steep cuts in the FDA's budget for the next fiscal year, the food division is expected to receive additional funds. Others noted the fine line agency officials were walking, given Kennedy's complaints that the FDA is too close to the drug industry and the Trump administration's business-friendly approach. Makary and Prasad wrote that the FDA must be 'partners with industry' while avoiding 'a cozy relationship that has characterized the agency in the past.' Dr. Reshma Ramachandran, a director of the Yale Collaboration for Regulatory Rigor, Integrity and Transparency, pointed out that Makary and Prasad were going on a six-city, closed-door listening tour to meet with chief executives of the drug industry. 'How is this guarding the agency 'against a cozy relationship' with industry?' she asked. The FDA priorities 'read as though they're straight out of PhRMA's playbook,' she said, referring to the trade group. Advertisement This article originally appeared in

Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034)
Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034)

Yahoo

time34 minutes ago

  • Yahoo

Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034)

The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including LUM-201 and SCO-240, among others. Furthermore, the rising prevalence of growth hormone deficiency, driven by improved diagnostics, higher survival rates of premature infants, increased pituitary disorders, and environmental factors like endocrine-disrupting chemicals, is expected to drive market growth for growth hormone replacement therapies. LAS VEGAS, June 10, 2025 /PRNewswire/ -- Growth hormone deficiency (GHD) is a rare condition resulting from inadequate secretion of growth hormone by the anterior pituitary gland. It can originate from birth, develop later in life, or have no known cause, underscoring the intricate mix of genetic, environmental, and diagnostic influences. Idiopathic cases are particularly difficult to address due to the absence of identifiable causes, revealing gaps in current understanding of the condition's underlying biology. According to DelveInsight, there were approximately 207,000 prevalent GHD cases across the 7MM in 2024, with around 165,000 diagnosed. This number is projected to increase by 2034. The United States accounted for the largest share of diagnosed prevalent cases in 2024, with roughly 70,000 cases—a figure expected to grow over the 2025–2034 forecast period. Current treatment options for GHD include approved therapies such as SOGROYA, SKYTROFA, and NGENLA. Standard treatment typically involves daily subcutaneous injections, which can be particularly burdensome for children, especially those with a fear of needles. Learn more about growth hormone deficiency treatment guidelines @ Growth Hormone Deficiency Treatment Market SOGROYA (somapacitan-beco) is a long-acting human growth hormone (hGH) analog that replicates the function of natural growth hormone. It's approved for children aged 2.5 years and older with growth failure due to insufficient endogenous GH and is also indicated as replacement therapy for adults with GHD. SOGROYA works by binding to a dimeric GH receptor on target cells, activating downstream signaling pathways, and producing effects largely mediated by liver-derived IGF-1. Key regulatory approvals include: FDA approval for adult GHD in August 2020 and for pediatric GHD in April 2023; EMA approval in March 2021; and PMDA approval in Japan for adult GHD in January 2021 and for pediatric growth issues in June 2023. SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd) is a pegylated, long-acting hGH formulated for once-weekly subcutaneous administration. It's approved in both the US and EU for pediatric patients (aged ≥1 year, ≥11.5 kg) with growth failure due to inadequate GH levels. It binds to GH receptors, initiating intracellular signaling and delivering both direct (e.g., tissue and metabolic regulation) and indirect (via IGF-1) effects, including chondrocyte development, increased hepatic glucose production, protein synthesis, and fat breakdown. Regulatory milestones include FDA approval in August 2021 for pediatric GHD, EU approval in January 2022 for patients aged 3–18, and an sBLA accepted by the FDA in December 2024 for adult GHD, with a PDUFA decision expected in July 2025. NGENLA (somatrogon-ghla) is another long-acting hGH analog developed to address inadequate natural GH production. Approved for children aged 3 and above with growth failure, NGENLA distinguishes itself from daily-injection therapies like GENOTROPIN by offering once-weekly dosing through an adjustable delivery device. It binds GH receptors and activates STAT5b signaling, leading to elevated IGF-1 and promoting linear growth and metabolic effects. NGENLA is approved in the US, EU, and Japan for pediatric GHD and is undergoing global Phase III trials for adult GHD. Regulatory highlights include US FDA approval in June 2023, European Commission approval in February 2022, and PMDA approval in January 2022. In July 2024, OPKO Health entered into a USD 250 million non-dilutive note agreement with HealthCare Royalty, backed by profit-sharing proceeds from its 2014 global partnership with Pfizer. Find out more on FDA-approved growth hormone deficiency treatment @ Growth Hormone Deficiency Drugs Market Existing treatments for growth hormone deficiency typically involve subcutaneous injections, available in both daily and newer weekly formats. However, the need for daily administration can be particularly difficult for children, often resulting in low adherence. To address this issue and enhance patient compliance, researchers are developing long-acting and oral alternatives. Companies like Lumos Pharma and SCOHIA PHARMA are advancing their candidates through clinical trials, contributing to innovation in the growth hormone deficiency space and opening up substantial opportunities for market growth. Discover which therapies are expected to grab major growth hormone deficiency market share @ Growth Hormone Deficiency Therapy LUM-201 (ibutamoren), an oral small molecule developed by Lumos Pharma, functions as an agonist of the growth hormone secretagogue receptor to stimulate the natural pulsatile release of growth hormone (GH). This targeted approach supports its use in conditions requiring enhanced GH production. Clinical studies have shown that LUM-201 is both safe and consistently effective in promoting GH secretion. Notably, the Phase II OraGrowtH210 and OraGrowtH212 trials in children with pediatric growth hormone deficiency (PGHD) successfully met all primary and secondary endpoints, reinforcing the drug's therapeutic value. In 2017, LUM-201 was granted orphan drug designation (ODD) in both the US and EU for treating growth hormone deficiency, which provides development incentives. Data presented at the European Society for Paediatric Endocrinology conference in November 2024 demonstrated sustained growth over 24 months, affirming the effectiveness of its pulsatile secretion mechanism. In December 2024, Double Point Ventures acquired Lumos Pharma through a tender offer, paying USD 4.25 per share along with contingent value rights. SCO-240, from SCOHIA PHARMA, is an oral small molecule that selectively blocks Somatostatin Receptor 5 (SSTR5), a receptor involved in hormonal regulation. While the exact function of SSTR5 in humans remains under investigation, SCO-240 has shown encouraging results in enhancing GH secretion. In a Phase I clinical study, the drug triggered significant GH release without disrupting other pituitary hormones, underscoring the therapeutic potential of SSTR5 antagonism for GH-related conditions. The compound exhibited a strong safety profile, was well-tolerated, and is suitable for once-daily oral use. In June 2023, findings from the study were presented at the 96th Annual Congress of the Japan Endocrine Society, highlighting its promise in treating GH deficiency, female infertility, and alopecia. In February 2024, SCO-240 was selected for AMED's Orphan Drug Prior to Designation support program, securing funding for its continued development in PGHD. Discover more about drugs for growth hormone deficiency in development @ Growth Hormone Deficiency Clinical Trials The anticipated launch of these emerging therapies for growth hormone deficiency are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the growth hormone deficiency market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for growth hormone deficiency is expected to grow from USD 1.4 billion in the 7MM in 2024 at a significant 5.7% CAGR by 2034. This growth across the 7MM is expected to be fueled by the launch of novel therapies such as LUM-201 and SCO-240, among others. Additionally, the increasing prevalence, attributed to advancements in diagnostic capabilities, improved survival rates of premature infants, a rise in pituitary disorders, and environmental influences like endocrine-disrupting chemicals, is projected to boost the demand for growth hormone replacement therapies. DelveInsight's latest published market report, titled as Growth Hormone Deficiency Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the growth hormone deficiency country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The growth hormone deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Pediatric Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Adult Growth Hormone Deficiency Gender-specific Cases of Growth Hormone Deficiency Etiology-specific Cases of Growth Hormone Deficiency The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM growth hormone deficiency market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this growth hormone deficiency market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the growth hormone deficiency market. Also, stay abreast of the mitigating factors to improve your market position in the growth hormone deficiency therapeutic space. Related Reports Growth Hormone Deficiency Epidemiology Forecast Growth Hormone Deficiency Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GHD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Growth Hormone Deficiency Pipeline Growth Hormone Deficiency Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GHD companies, including Novo Nordisk, Ascendis Pharma, among others. Adult Growth Hormone Deficiency Market Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adult growth hormone deficiency companies, including Novo Nordisk, Ascendis Pharma, among others. Pediatric Growth Hormone Deficiency Market Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric growth hormone deficiency companies, including TJ Biopharma, Lumos Pharma, SCOHIA PHARMA, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Melden Sie sich an, um Ihr Portfolio aufzurufen.

FDA OKs New Shot to Protect Babies Against RSV
FDA OKs New Shot to Protect Babies Against RSV

WebMD

time38 minutes ago

  • WebMD

FDA OKs New Shot to Protect Babies Against RSV

June 10, 2025 – The FDA has approved a new shot to prevent respiratory syncytial virus (RSV) infection in babies during their first RSV season, which typically lasts from fall through spring. Clesrovimab, which is sold as Enflonsia, is the first and only RSV protection for babies that uses the same dose for all infants, regardless of their body weight. This makes it a simpler and more precise option that ensures reliable protection throughout the RSV season. RSV is a common virus that spreads during colder months through coughs, sneezes, direct contact, or contaminated surfaces. It typically causes mild, cold-like symptoms. Infants (especially those under 6 months) and older adults are more likely to have a severe RSV infection. RSV can cause bronchiolitis (inflammation of small airways) and pneumonia, sometimes leading to hospitalization. Because it's the leading cause of hospitalization in infants, vaccines and preventive treatments are the best way to protect them. Merck, the maker of the new preventive, said the FDA's decision was based on two clinical trials. In the first trial, a single dose of Enflonsia was given to newborns, both preterm and full-term, and reduced RSV severe lung infections by 60% and hospitalizations by 84% over five months, compared to a placebo. The second trial showed Enflonsia was as effective and safe as an older RSV medicine (palivizumab) for babies at higher risk, such as those born very early or with lung or heart issues. The clinical trials also showed that Enflonsia was just as safe on its own or with other routine childhood vaccines. "Enflonsia combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV," Octavio Ramilo, MD, chair of the Department of Infectious Diseases at St. Jude Children's Research Hospital and investigator for the clinical trials, said in a statement. The Enflonsia shot contains ready-made antibodies that help newborns and infants fight off RSV before it can cause serious lung infections. It uses a single, non-weight-based, 105-mg dose that gives fast and lasting protection for about five months. Babies born during RSV season should get the shot at birth, while those born before the season should get it just before it starts. The preventive is given as an injection in the baby's thigh.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store